193 related articles for article (PubMed ID: 31519508)
21. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
Elife; 2023 Feb; 12():. PubMed ID: 36852480
[TBL] [Abstract][Full Text] [Related]
22. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
[TBL] [Abstract][Full Text] [Related]
23. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity.
Obermann W; Friedrich A; Madhugiri R; Klemm P; Mengel JP; Hain T; Pleschka S; Wendel HG; Hartmann RK; Schiffmann S; Ziebuhr J; Müller C; Grünweller A
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336926
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.
Bordeleau ME; Mori A; Oberer M; Lindqvist L; Chard LS; Higa T; Belsham GJ; Wagner G; Tanaka J; Pelletier J
Nat Chem Biol; 2006 Apr; 2(4):213-20. PubMed ID: 16532013
[TBL] [Abstract][Full Text] [Related]
25. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
26. eIF4B stimulates translation of long mRNAs with structured 5' UTRs and low closed-loop potential but weak dependence on eIF4G.
Sen ND; Zhou F; Harris MS; Ingolia NT; Hinnebusch AG
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10464-72. PubMed ID: 27601676
[TBL] [Abstract][Full Text] [Related]
27. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.
Agarwal G; Chang LS; Soejarto DD; Kinghorn AD
Planta Med; 2021 Oct; 87(12-13):937-948. PubMed ID: 33784769
[TBL] [Abstract][Full Text] [Related]
28. eIF4A inhibitors PatA and RocA stack the deck against translation.
Ingolia NT
Structure; 2021 Jul; 29(7):638-639. PubMed ID: 34214439
[TBL] [Abstract][Full Text] [Related]
29. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation.
Bordeleau ME; Cencic R; Lindqvist L; Oberer M; Northcote P; Wagner G; Pelletier J
Chem Biol; 2006 Dec; 13(12):1287-95. PubMed ID: 17185224
[TBL] [Abstract][Full Text] [Related]
30. Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
Ho JJD; Cunningham TA; Manara P; Coughlin CA; Arumov A; Roberts ER; Osteen A; Kumar P; Bilbao D; Krieger JR; Lee S; Schatz JH
Cell Rep; 2021 Oct; 37(2):109806. PubMed ID: 34644561
[TBL] [Abstract][Full Text] [Related]
31. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
Tillotson J; Kedzior M; Guimarães L; Ross AB; Peters TL; Ambrose AJ; Schmidlin CJ; Zhang DD; Costa-Lotufo LV; Rodríguez AD; Schatz JH; Chapman E
Bioorg Med Chem Lett; 2017 Sep; 27(17):4082-4085. PubMed ID: 28757063
[TBL] [Abstract][Full Text] [Related]
32. Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.
Itoua Maïga R; Cencic R; Chu J; Waller DD; Brown LE; Devine WG; Zhang W; Sebag M; Porco JA; Pelletier J
Sci Rep; 2019 Feb; 9(1):1265. PubMed ID: 30718665
[TBL] [Abstract][Full Text] [Related]
33. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.
Taroncher-Oldenburg G; Müller C; Obermann W; Ziebuhr J; Hartmann RK; Grünweller A
Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33807988
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
[TBL] [Abstract][Full Text] [Related]
35. Coupling between the DEAD-box RNA helicases Ded1p and eIF4A.
Gao Z; Putnam AA; Bowers HA; Guenther UP; Ye X; Kindsfather A; Hilliker AK; Jankowsky E
Elife; 2016 Aug; 5():. PubMed ID: 27494274
[TBL] [Abstract][Full Text] [Related]
36. Comparing the Effects of Rocaglates on Energy Metabolism and Immune Modulation on Cells of the Human Immune System.
Schiffmann S; Henke M; Seifert M; Ulshöfer T; Roser LA; Magari F; Wendel HG; Grünweller A; Parnham MJ
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982945
[TBL] [Abstract][Full Text] [Related]
37. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R; Im YK; Naineni SK; Moustafa-Kamal M; Jovanovic P; Sabourin V; Annis MG; Robert F; Schmeing TM; Koromilas A; Paquet M; Teodoro JG; Huang S; Siegel PM; Topisirovic I; Ursini-Siegel J; Pelletier J
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2318093121. PubMed ID: 38232291
[TBL] [Abstract][Full Text] [Related]
38. Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity.
Low WK; Dang Y; Bhat S; Romo D; Liu JO
Chem Biol; 2007 Jun; 14(6):715-27. PubMed ID: 17584618
[TBL] [Abstract][Full Text] [Related]
39. Small-Molecule Inhibitors Targeting eIF4A in Leukemia.
Jia X; Zhou H
Curr Protein Pept Sci; 2021; 22(7):559-566. PubMed ID: 34042032
[TBL] [Abstract][Full Text] [Related]
40. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
